BioAge Labs (NASDAQ:BIOA – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.
Valuation & Earnings
This table compares BioAge Labs and Sol-Gel Technologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioAge Labs | $8.60 million | 31.33 | -$80.61 million | ($2.55) | -2.30 |
| Sol-Gel Technologies | $1.79 million | 114.42 | -$6.13 million | ($5.64) | -11.12 |
Sol-Gel Technologies has lower revenue, but higher earnings than BioAge Labs. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
BioAge Labs has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Profitability
This table compares BioAge Labs and Sol-Gel Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioAge Labs | -1,253.60% | -31.42% | -29.59% |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
Analyst Recommendations
This is a summary of current ratings and target prices for BioAge Labs and Sol-Gel Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioAge Labs | 1 | 1 | 6 | 0 | 2.62 |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
BioAge Labs currently has a consensus target price of $33.00, suggesting a potential upside of 462.18%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 214.84%. Given BioAge Labs’ higher probable upside, equities analysts clearly believe BioAge Labs is more favorable than Sol-Gel Technologies.
Institutional & Insider Ownership
26.2% of Sol-Gel Technologies shares are owned by institutional investors. 17.5% of BioAge Labs shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Sol-Gel Technologies beats BioAge Labs on 8 of the 15 factors compared between the two stocks.
About BioAge Labs
BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates. BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd. is a dermatology-focused specialty pharmaceutical company based in Israel. The company develops and commercializes topical prescription medicines for common skin conditions, using proprietary delivery technologies designed to improve the stability, tolerability, and effectiveness of active pharmaceutical ingredients. Its marketed products include Epsolay, a topical benzoyl peroxide cream indicated for the treatment of inflammatory lesions associated with rosacea, and Twyneo, a fixed-dose topical combination of tretinoin and benzoyl peroxide for acne vulgaris.
Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.
